UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026185
Receipt number R000021729
Scientific Title Effect of oral hypoglycemic agent for postprandial hyperglycemia administered two times daily on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets
Date of disclosure of the study information 2017/02/17
Last modified on 2018/08/20 14:34:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of oral hypoglycemic agent for postprandial hyperglycemia administered two times daily on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets

Acronym

Effect of twice daily administration on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets.

Scientific Title

Effect of oral hypoglycemic agent for postprandial hyperglycemia administered two times daily on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets

Scientific Title:Acronym

Effect of twice daily administration on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets.

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effect of oral hypoglycemic agent for postprandial hyperglycemia administered two times daily on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

HbA1c

Comparison at16weeks,24 weeks from the start of administration

Key secondary outcomes

GA
1.5AG
Fasting blood glucose
Fasting insulin
HOMA-R
Serum CPR


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Mitiglinide calcium hydrate administration group

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients are being treated with diet therapy and DPP-4 inhibitor, metformin for more than 8 weeks (56 days) prior to the start of the study.
2)HbA1c (NGSP) before clinical trial start is 7.0% or more and 9.0% or less.
3)Patients are not clinically problematic anemia.
4)over 20 years age
5)Out patient
6)Patients who provided written consent

Key exclusion criteria

1) Patients with contraindications against the use of mitiglinide calcium hydrate tablets and mitiglinide calcium hydrate/voglibose combimation tablets based on their package inserts.
2) Patients who had taken sulfonylureas, GLP-1 receptor agonists,glinide,a-GI, SGLT-2 inhibitors, insulin within 8 weeks (56 days) before the start of the study
3) Excessive drinkers
4) Patients with severe diabetic microangiopathy
5) Patients with severe liver / kidney function decline
6) Patients with severe heart disease
7) Patients with severe hypertension combined
8) Patients with open surgery or previous bowel obstruction
9)Patients who were judged to be ineligible to be ineligible by the investigator or sub-investigator

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasushi Tanaka

Organization

St.Marianna University School of Medicine

Division name

Division of Endocrinology and Metabolism

Zip code


Address

2-16-1

TEL

044-977-8111

Email

y2tanaka@marianna-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroyuki Kato

Organization

St.Marianna University School of Medicine Hospital

Division name

Division of Endocrinology and Metabolism

Zip code


Address

2-16-1 Sugou, Miyamae-ku Kawasaki-city Kanagawa-ken

TEL

044-977-8111

Homepage URL


Email

h.k.kato@marianna-u.ac.jp


Sponsor or person

Institute

St.Marianna University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kissei Pharmaceutical Co

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 05 Month 31 Day

Date of IRB


Anticipated trial start date

2016 Year 05 Month 31 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 02 Month 17 Day

Last modified on

2018 Year 08 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021729


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name